Literature DB >> 9032189

Combined inhalation of nitric oxide and oxygen in chronic obstructive pulmonary disease.

M Yoshida1, O Taguchi, E C Gabazza, T Kobayashi, T Yamakami, H Kobayashi, K Maruyama, T Shima.   

Abstract

Inhaled nitric oxide (NO) has been shown to reduce the mean pulmonary artery pressure (mPAP) and to improve PaO2 in patients with acute respiratory failure undergoing oxygen (O2) therapy. However, inhaled NO reduced pulmonary hypertension without improving PaO2 in patients with chronic obstructive pulmonary disease (COPD). This study was intended to compare the hemodynamic and gas exchange responses during inhalation of NO or O2 with those observed during the combined inhalation of NO and O2 in 10 spontaneously breathing COPD patients. Hemodynamic and blood gas parameters were measured after breathing: (1) room air; (2) NO added to room air; (3) O2 (1 L/min); or (4) NO and O2. During inhalation of 2 ppm NO added to room air, the mPAP (23.1 +/- 2.5 versus 20.6 +/- 2.2 mm Hg) and the pulmonary vascular resistance (PVR) (434 +/- 70 versus 378 +/- 50 dyne s/cm5) were significantly (p < 0.05) lower than those measured with room air. However, the values of PaO2 did not improve. The combined inhalation of NO and O2 was associated not only with a significant (p < 0.05) decrease of mPAP (21.4 +/- 2.3 versus 19.7 +/- 1.8 mm Hg) and PVR (431 +/- 72 versus 370 +/- 44 dyne s/cm5), but also with a remarkable improvement (p < 0.05) in the values of PaO2 (91.4 +/- 6.6 versus 111.5 +/- 7.8 mm Hg) as compared with values obtained during the inhalation of O2 alone. These findings suggest that combined therapy with NO and O2 may constitute an alternative approach to treating patients with COPD and pulmonary hypertension.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9032189     DOI: 10.1164/ajrccm.155.2.9032189

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  15 in total

1.  Use of nitric oxide inhalation in chronic obstructive pulmonary disease.

Authors:  K Ashutosh; K Phadke; J F Jackson; D Steele
Journal:  Thorax       Date:  2000-02       Impact factor: 9.139

2.  A European survey of the use of inhaled nitric oxide in the ICU. Working Group on Inhaled NO in the ICU of the European Society of Intensive Care Medicine.

Authors:  S Beloucif; D Payen
Journal:  Intensive Care Med       Date:  1998-08       Impact factor: 17.440

3.  Controlled prospective randomised trial on the effects on pulmonary haemodynamics of the ambulatory long term use of nitric oxide and oxygen in patients with severe COPD.

Authors:  K Vonbank; R Ziesche; T W Higenbottam; L Stiebellehner; V Petkov; P Schenk; P Germann; L H Block
Journal:  Thorax       Date:  2003-04       Impact factor: 9.139

Review 4.  Pulmonary hypertension in patients with chronic obstructive pulmonary disease: advances in pathophysiology and management.

Authors:  Joan Albert Barberà; Isabel Blanco
Journal:  Drugs       Date:  2009-06-18       Impact factor: 9.546

Review 5.  Recognition and management of pulmonary hypertension.

Authors:  J C Wanstall; T K Jeffery
Journal:  Drugs       Date:  1998-12       Impact factor: 9.546

Review 6.  Inhaled NO as a therapeutic agent.

Authors:  Kenneth D Bloch; Fumito Ichinose; Jesse D Roberts; Warren M Zapol
Journal:  Cardiovasc Res       Date:  2007-05-04       Impact factor: 10.787

Review 7.  Hypoxic pulmonary vasoconstriction.

Authors:  J T Sylvester; Larissa A Shimoda; Philip I Aaronson; Jeremy P T Ward
Journal:  Physiol Rev       Date:  2012-01       Impact factor: 46.500

8.  Acute hemodynamic effects of inhaled nitric oxide, dobutamine and a combination of the two in patients with mild to moderate secondary pulmonary hypertension.

Authors:  C D Vizza; G D Rocca; A D Roma; C Iacoboni; F Pierconti; F Venuta; E Rendina; G Schmid; P Pietropaoli; F Fedele
Journal:  Crit Care       Date:  2001-10-09       Impact factor: 9.097

9.  Formulation, preclinical and clinical evaluation of a new submicronic arginine respiratory fluid for treatment of chronic obstructive pulmonary disorder.

Authors:  Virendra Pratap Singh Rathor; Pradeep Chugh; Rashid Ali; Anuj Bhatnagar; Syed Ehtaishamul Haque; Aseem Bhatnagar; Gaurav Mittal
Journal:  Saudi Pharm J       Date:  2015-03-20       Impact factor: 4.330

10.  Vasodilatory effect of the stable vasoactive intestinal peptide analog RO 25-1553 in murine and rat lungs.

Authors:  Jun Yin; Liming Wang; Ning Yin; Arata Tabuchi; Hermann Kuppe; Gerhard Wolff; Wolfgang M Kuebler
Journal:  PLoS One       Date:  2013-09-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.